The nurse is administering glycopyrrolate to an end of life client. What is the expected outcome of this drug?

Rationale: A. Decreased heart rate and blood pressure: Glycopyrrolate is an anticholinergic agent that blocks muscarinic receptors, which generally leads to increased heart rate rather than a decrease. It does not have significant hypotensive effects and is not used to control cardiovascular parameters in end-of-life care. B. Increased general muscle paralysis: Glycopyrrolate does not act on skeletal muscles or neuromuscular junctions. Its pharmacologic effect is primarily on the parasympathetic nervous system, so it does not cause muscle paralysis or enhance neuromuscular blockade. C. Decreased respiratory tract secretions: Glycopyrrolate reduces salivary, bronchial, and tracheal secretions by inhibiting muscarinic cholinergic receptors. In end-of-life care, this helps minimize respiratory secretions and the "death rattle," improving comfort and reducing airway obstruction. D. Increased GI motility and urine output: Glycopyrrolate has anticholinergic effects that actually decrease gastrointestinal motility and can cause urinary retention. It does not promote GI peristalsis or diuresis and is therefore not expected to increase these functions.